{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "be:PDE",
      "entity_text" : "phosphodiesterase",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:2754",
      "entity_text" : "Cilostazol",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Cilostazol, another drug in the combination treatment in this study, is an inhibitor of type 3 phosphodiesterase that exerts antiplatelet activity through the suppression of cAMP degradation and also has pleiotropic effects against inflammation on vascular function and atherosclerosis.",
  "reading_complete" : "2020-08-03T13:58:59Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T13:57:44Z",
  "trigger" : "is an inhibitor",
  "evidence" : [ "Cilostazol, another drug in the combination treatment in this study, is an inhibitor of type 3 phosphodiesterase" ],
  "pmc_id" : "4121353",
  "score" : 0
}